Neuro-oncology in 2013: Improving outcome in newly diagnosed malignant glioma

Nature Reviews Neurology

Volumn 10, Issue 2, 2014, Pages 68-70

  Weller, Michael ^a   Wick, Wolfgang ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NEOPLASMS; GLIOMA; HISTORY, 21ST CENTURY; HUMANS; MEDICAL ONCOLOGY; NEUROLOGY; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84893849602     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.268     Document Type: Review

References (10)

1. Weller, M. et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 14, e370-e379 (2013).
2. Sturm, D. etal. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425-437 (2012).
3. Brennan, C.W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-467 (2013).
4. Van den Bent, M. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 31, 344-350 (2013).
5. Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337-343 (2013).
6. Wick, W. et al. NOA?04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874-5880 (2009).
7. Wick, W. et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81, 1515-1522 (2013).
8. Chinot, O. et al. Bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. (in press).
9. Gilbert, M.R. et al. Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). N. Engl. J. Med. (in press).
10. Wefel, J.S. et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 13, 660-668 (2011).